Pune, Maharastra -- (SBWIRE) -- 11/23/2015 -- The availability of funding for the development of drugs used in the treatment of diseases caused by drug resistant bacteria is providing an encouragement for more manufacturers to enter the Antibacterial Drugs market. Also, the strategic alliances formed between the vendors help in increased penetration of the drugs in the market and increase market share.
The analysts forecast global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019.To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The various classes of antibacterial drug included in this report are beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, folate antagonists, tetracyclines, and other miscellaneous agents, which include glycopeptides, nitroimidazoles, lincosamides, lipopeptides, nicotinic acid derivatives, and polypeptide antibiotics.
According to the report, the special regulatory designations provided for the development of antibiotic drugs is one of the major drivers for the growth of the market. The Generating Antibiotics Incentives Now (GAIN) Act by US FDA provides QIDP designation for pipeline molecules. This designation helps in the faster development of drugs along with eligibility for priority reviews for NDA
Further, the report states that the development of multidrug-resistant microbes due to the irrational use of antibacterial drugs increases the severity of the infections often leading to the death of the individual. This is affecting market growth as mortality rates are increasing.
Order a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=430638.
The following companies are the key players in the Global Antibacterial Drugs Market: Allergan, GSK, Merck, Pfizer, Sandoz and Teva Pharmaceuticals
Other Prominent Vendors in the market are: Abbott, Achaogen, Actelion, AmpliPhi Biosciences, Aspen Pharmacare, Astellas, AstraZeneca, Aurobindo Pharma, Baxter, Basilea Pharmaceuticals, Bayer, Biocon, Bristol-Myers Squibb, Cempra, Cipher Pharmaceuticals, Corden Pharma, Cornerstone Therapeutics, Eli Lilly, Exoxemis, F.Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, InSite Vision, Insmed Incorporated, Johnson & Johnson, KaloBios Pharmaceuticals, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Lytix Biopharma, Melinta Therapeutics, Mylan, Nektar, Orchid Pharma, Par Pharmaceutical, Paratek Pharmaceuticals , Pernix Therapeutics, PTC Therapeutics, RedHill Biopharma, Sagent Pharmaceuticals, Sanofi , Shionogi, Starpharma, Sun Pharmaceutical, Symbiomix , Takeda Pharma, Tetraphase Pharmaceuticals, Theravance Biopharma, The Medicines Company, Valneva, and Wockhardt.
Single User License Copy is for US $3000, get DISCOUNT at http://www.rnrmarketresearch.com/contacts/discount?rname=430638.
About RnRMarketResearch.com
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.